Quick Answer
GYRE THERAPEUTICS, INC. reported Long-Term Debt of $283.0 thousand for fiscal year 2013.
GYRE THERAPEUTICS, INC. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2013 | $283.0K | -75.1% |
| 2012 | $1.14M | -42.8% |
| 2011 | $1.99M | +47.2% |
| 2010 | $1.35M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| March 31, 2014 | $142.0K | -84.5% | -49.8% |
| December 31, 2013 | $283.0K | -75.1% | -40.8% |
| September 30, 2013 | $478.0K | -64.6% | -31.6% |
| June 30, 2013 | $699.0K | -55.3% | -23.9% |
| March 31, 2013 | $918.0K | -48.3% | -19.2% |
| December 31, 2012 | $1.14M | -42.8% | -15.9% |
| September 30, 2012 | $1.35M | -38.5% | -13.6% |
| June 30, 2012 | $1.56M | -35.8% | -11.9% |
- GYRE THERAPEUTICS, INC. showed a decrease of -75.1% in Long-Term Debt compared to the prior fiscal year.
- Over the 2010–2013 period, GYRE THERAPEUTICS, INC.’s long-term debt has declined by 79.0% (from $1.35 million to $283.0 thousand).
- The most recent figure is from GYRE THERAPEUTICS, INC.’s fiscal year 2014 report (Form 10-K), filed with the SEC on March 16, 2015.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: